- Home
- PROP vs TIL Comparison
PROP vs TIL Comparison
Compare PROP & TIL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | PROP | TIL |
|---|---|---|
| Founded | 2001 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Bankers/Brokers/Service | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 44.9M | 52.2M |
| IPO Year | 2008 | 2021 |
Fundamental Metrics
Financial Performance| Metric | PROP | TIL |
|---|---|---|
| Price | $0.42 | $6.90 |
| Analyst Decision | Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $1.50 | N/A |
| AVG Volume (30 Days) | ★ 1.1M | 49.4K |
| Earning Date | 11-13-2026 | 11-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 49.06 | 6.06 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $7,939,000.00 | N/A |
| Revenue This Year | $85.81 | N/A |
| Revenue Next Year | $11.47 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 413.59 | N/A |
| 52 Week Low | $0.32 | $5.56 |
| 52 Week High | $2.55 | $18.13 |
Technical Indicators
Market Signals| Indicator | PROP | TIL |
|---|---|---|
| Relative Strength Index (RSI) | 52.91 | 57.54 |
| Support Level | $0.38 | N/A |
| Resistance Level | $0.44 | $7.75 |
| Average True Range (ATR) | 0.04 | 0.45 |
| MACD | 0.01 | 0.10 |
| Stochastic Oscillator | 56.11 | 83.97 |
Price Performance
Historical ComparisonAbout PROP Prairie Operating Co.
Prairie Operating Co is an independent oil and natural gas company focused on the acquisition and development of crude oil, natural gas, and natural gas liquids (NGLs). Its assets and operations are located in the oil region of rural Weld County, Colorado, within the Denver-Julesburg Basin in Colorado (the DJ Basin). The company generates maximum revenue from crude oil sales, and the rest from the sale of natural gas and natural gas liquids.
About TIL Instil Bio Inc.
Instil Bio Inc is a clinical-stage biopharmaceutical company focused on developing a cell therapy pipeline of autologous tumor infiltrating lymphocyte, or TIL, therapies for the treatment of patients with cancer. It is also engaged in developing a novel class of genetically engineered TIL therapies using its Co-Stimulatory Antigen Receptor, or CoStAR, platform. Its pipeline includes ITIL-306 which expresses a CoStAR molecule designed to recognize, a tumor-associated antigen that is expressed on numerous solid tumors, including ovarian cancer, uterine cancer, NSCLC, and renal cancer.